Details Cookies
United Kingdom
Important margin product information

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 73% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs, FX or any of our other products work and whether you can afford to take the high risk of losing your money.

Cookie policy

This website uses cookies to offer you a better browsing experience by enabling, optimising and analysing site operations, as well as to provide personalised ad content and allow you to connect to social media. By choosing “Accept all” you consent to the use of cookies and the related processing of personal data. Select “Manage consent” to manage your consent preferences. You can change your preferences or retract your consent at any time via the cookie policy page. Please view our cookie policy here and our privacy policy here

Earnings Watch: AMD, Novo Nordisk, and Apple Earnings Watch: AMD, Novo Nordisk, and Apple Earnings Watch: AMD, Novo Nordisk, and Apple

Earnings Watch: AMD, Novo Nordisk, and Apple

Peter Garnry

Head of Equity Strategy

Summary:  The Q1 earnings season has been better than feared showing companies that are still confident about the outlook and the technology sector is showing so far that operating income is growing again following significant cost-cutting. In this week's earnings we focus on AMD, Novo Nordisk, and Apple where all three companies face quite steep expectations from investors following strong share price performances this year.

Technology is back in growth mode

The significant amount of cost-cutting among technology companies is beginning to yield results for technology companies with Nasdaq 100 expanding EBITDA in Q1 q/q while both the S&P 500 and the STOXX 600 are so far reporting declines in EBITDA q/q. Another key observation is that European companies continue to do well relative to US companies underpinning the case for European equities this year. The US companies are always leading the earnings season so these conclusions may change before the season is over and this week’s results from AMD and Apple could change the positive turnaround in operating income that we are observing so far in the Nasdaq 100. While US equities have come back recently, the main risk and issue with US equities remain the high equity valuation relative to other equity markets and with a 12-month 12.8x EV/EBITDA the US equity market comes with a significant valuation premium to global equities.

Another busy earnings week with focus on AMD, Novo Nordisk, and Apple

The three stocks we are focusing on for this week’s earnings releases are AMD, Novo Nordisk, and Apple because there are all popular companies, with strong growth record, and important for their respective industries.

Will AMD continue to ride the AI hype?

AMD reports Q1 earnings tomorrow after the US market close with analysts expecting revenue of $5.3bn down 10% y/y and EBITDA of $1.27bn down from $1.71bn a year ago reflecting increased input costs and lower demand as corporate technology spending is declining and gaming is not as hot as during the pandemic. With expectations set low for Q1 we expect AMD to clear this bar easily, but expectations are certainly steeper for the coming quarters as the AI hype with ChatGPT has lifted AMD’s share price 38% this year and thus the Q2 guidance will be key for the market’s reaction.

Novo Nordisk is up against extreme expectations

Novo Nordisk reports Q1 earnings on Thursday before the market opens in Copenhagen with analysts expecting Q1 revenue of DKK 51.8bn up 23% y/y and EBITDA of DKK 25bn up from DKK 20.8bn a year ago driven by strong growth in the company’s weight loss drug Wegovy. Back in early February we wrote a game changer equity note on Novo Nordisk with a special focus on Wegovy as the company’s next important growth driver. Novo Nordisk has got a head start on this new class of weight loss drugs with Eli Lilly waiting for its FDA approval and the market is really excited about the growth outlook sending Novo Nordisk shares up 21% this year.

Can Apple get back to above average growth?

Apple reports FY23 Q2 earnings (ending 31 March) on Thursday after the market close with analysts expecting revenue of $92.6bn down 5% y/y and EBITDA of $30.2bn down from $32.7bn a year ago as input costs remain hot demand has been negatively impacted by high inflation in key markets reducing consumers appetite for Apple’s pricier electronic devices such as the iPhone. We expect Apple to guide weak Mac sales and the risk has gone up that iPhone guidance could disappoint as well. With the share price up 31% this year expectations might be too high for even Apple.

AMD, Novo Nordisk, and Apple weekly total return the past five years | Source: Bloomberg

The list below shows all the most important earnings releases to watch this week with especially Thursday being the main course with key earnings from Shopify on e-commerce, Maersk on logistics, Volkswagen and BMW on EV growth, Infineon on semiconductor pick-up, Rheinmetall on EU military spending, Zalando on EU consumer spending, Shell on energy markets, ArcelorMittal on steel demand, Booking on travel, Ferrari on luxury, and lastly Fortinet on cyber security.

  • Monday: Berkshire Hathaway, Stryker, Vertex Pharmaceuticals, NXP Semiconductors

  • Tuesday: Thomson Reuters, HSBC, BP, DBS Group, Geberit, Pfizer, AMD, Starbucks, Uber Technologies, Marathon Petroleum, Ford Motor

  • Wednesday: Barrick Gold, Orsted, Airbus, BNP Paribas, Deutsche Post, Enel, UniCredit, Lloyds Banking Group, Qualcomm, CVS Health, Estee Lauder, MercadoLibre, Kraft Heinz

  • Thursday: National Australia Bank, Anheuser-Busch InBev, Shopify, Novo Nordisk, Maersk, Volkswagen, BMW, Infineon Technologies, Uniper, Rheinmetall, Zalando, Shell, ArcelorMittal, Equinor, Apple, ConocoPhillips, Booking, Regeneron Pharmaceuticals, Zoetis, Becton Dickinson, EOG Resources, Ferrari, Fortinet

  • Friday: ANZ, Macquire Group, Enbridge, Canadian Natural Resources, Adidas, Intesa Sanpaolo, CaixaBank, Cigna Group


The Saxo Bank Group entities each provide execution-only service and access to Analysis permitting a person to view and/or use content available on or via the website. This content is not intended to and does not change or expand on the execution-only service. Such access and use are at all times subject to (i) The Terms of Use; (ii) Full Disclaimer; (iii) The Risk Warning; (iv) the Rules of Engagement and (v) Notices applying to Saxo News & Research and/or its content in addition (where relevant) to the terms governing the use of hyperlinks on the website of a member of the Saxo Bank Group by which access to Saxo News & Research is gained. Such content is therefore provided as no more than information. In particular no advice is intended to be provided or to be relied on as provided nor endorsed by any Saxo Bank Group entity; nor is it to be construed as solicitation or an incentive provided to subscribe for or sell or purchase any financial instrument. All trading or investments you make must be pursuant to your own unprompted and informed self-directed decision. As such no Saxo Bank Group entity will have or be liable for any losses that you may sustain as a result of any investment decision made in reliance on information which is available on Saxo News & Research or as a result of the use of the Saxo News & Research. Orders given and trades effected are deemed intended to be given or effected for the account of the customer with the Saxo Bank Group entity operating in the jurisdiction in which the customer resides and/or with whom the customer opened and maintains his/her trading account. Saxo News & Research does not contain (and should not be construed as containing) financial, investment, tax or trading advice or advice of any sort offered, recommended or endorsed by Saxo Bank Group and should not be construed as a record of our trading prices, or as an offer, incentive or solicitation for the subscription, sale or purchase in any financial instrument. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, would be considered as a marketing communication under relevant laws.

Please read our disclaimers:
- Notification on Non-Independent Investment Research (
- Full disclaimer (

Saxo Markets
40 Bank Street, 26th floor
E14 5DA
United Kingdom

Support Centre
For existing clients, please click here to request support via the Support Centre.

Have a question about our products, platforms or services? Visit the Support Centre to find answers for our most frequently asked questions. If you are still unable to locate an answer to your question, you will also find contact details for your local Saxo office to speak with a representative.

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo Markets is a registered Trading Name of Saxo Capital Markets UK Ltd (‘SCML’). SCML is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo Markets assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.